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INTRODUCTION 
The academic field of cancer health disparities was stimulated by the US civil rights movement. 
Concerns about civil rights led to concerns about equality in health care. The first publications to 
make the observation that black Americans have higher rates of death as a result of certain 
cancers compared with white Americans were published the early 1970s.
1,2
 The discipline 
concerned with these differences was first called “minority health research” and later “special 
populations health” or “special populations research.” The National Cancer Institute (NCI) 
defines cancer health disparities as adverse differences in cancer incidence, cancer prevalence, 
cancer mortality, cancer survivorship, and burden of cancer or related health conditions that exist 
among specific population groups in the United States.
3
 However, with greater and renewed 
acknowledgment of health disparities as rooted within the context of historical and contextual 
inequities in the United States, many health disparities are considered health inequities.
4 
 
The National Cancer Act of 1971 created the Surveillance, Epidemiology, and End Results 
(SEER) program within the NCI. This program began collecting incidence, mortality, and 
survival data by race in the early 1970s from a number of population-based registries around the 
United States. The SEER program improved documentation of differences in outcomes and 
analyzed them through its black-white studies.
5
 These studies especially demonstrated 
differences in treatment patterns, with a higher proportion of blacks receiving inappropriate 
cancer care compared with whites. 
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The discipline grew from a focus on black-white differences to encompass differences in 
outcomes for a number of racial and ethnic groups, as well as for cohorts defined by age, sex, 
socioeconomic status (SES), and other social determinants of health. There is now even greater 
appreciation for disparities among communities, whether rural versus urban or even by state or 
region. The definition of health outcomes also broadened beyond death rates. 
 
The field of health disparities was once simply a description of population differences and a call 
for cultural competence among health care providers. Today, the field is transdisciplinary, 
integrating basic science, clinical science, policy, epidemiology, and the social sciences. It 
involves people trained in diverse nonmedical fields, such as education, economics, sociology, 
religion, geography, and anthropology. The field is also dynamic. It changes as better and more 
granular statistics, greater understanding of causes of health disparities, and new challenges to 
mitigate these underlying causes have emerged. As an example, in the 1970s, the breast cancer 
death rate for black and white American women was the same. Today, the age-adjusted survival 
rate for black women is lower than for white women.
6
 Policy changes have also created 
opportunities and challenges. The Affordable Care Act has allowed for Medicaid expansion in 
each state. Expansion has been adopted by 32 states and the District of Columbia. This will 
create a new challenge, because poor residents of some states have expanded access to care and 
residents of other states do not. Population categorizations also are being redefined. The Asian 
category includes Korean Americans and Pakistani Americans. The Pacific Islander category, 
often merged with the Asian category, includes native Hawaiians and Samoans. These 
populations are incredibly heterogeneous and have dramatically different cancer statistics. 
 
In 2015, representatives from four leading cancer organizations: The American Association for 
Cancer Research, the American Cancer Society, ASCO, and the NCI, began to meet to discuss 
the state of health disparities in the United States. These discussions involved the state of cancer 
health disparities research and what could be done to move it forward. The discussions were 
purposely not meant as a comprehensive review of cancer health disparities research. Rather, the 
meeting and the resulting document aimed to identify issues in health disparities research and 
make specific recommendations to improve the way disparities research is conducted and 
disseminated. 
 
This statement presents a unified strategy among four of the leading cancer organizations in the 
United States to promote cooperation among investigators in all areas of the cancer health 
disparities research community, to ensure that cancer research benefits all populations and 
patients regardless of race, ethnicity, age, gender identity, sexual orientation, SES, or the 
communities in which they live. 
 
DEFINING MEASURES AND TOOLS FOR THE NEXT GENERATION OF CANCER 
HEALTH DISPARITIES RESEARCH 
Background 
Disparities in outcomes across the cancer continuum have been identified in numerous medically 
underserved populations, including racial and ethnic minorities and patients of lower SES. In 
addition to individual social status, social contextual and community factors, such as 
neighborhood safety, social cohesion, availability of healthy foods, and residential segregation, 
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play an important role in health of both individuals and populations. All of these factors can 
intersect to generate larger disparities.
7,8
 
 
Current Issues/State of Knowledge 
To understand and fully address cancer health disparities, complete, consistent, and accurate 
collection of patient, community, and structural factors that put people at risk for disparate 
outcomes is essential. Unfortunately, cancer health disparities research has often been fraught 
with missing, inaccurate, or overly simplified patient-level data, and most research has failed to 
consider the community-level factors described above.
9-11
 
 
For the most part, the manner in which data are collected and integrated in disparities research is 
suboptimal. The literature is characterized by variable methodology for collection of the factors 
that put patients and communities at risk for disparate care and outcomes. For example, although 
race and ethnicity are distinct constructs, they are often conflated such that a person is identified 
as Hispanic without identification of his or her race. Many studies that investigate cancer care or 
outcomes according to socioeconomic position have only area-level data on socioeconomic 
position, whereas others use only composite measures. While valuable in many cases in 
identifying disparities, such measures fall short in providing the richness of data needed to 
understand an individual’s socioeconomic position. Health literacy and numeracy are rarely 
assessed in practice and are not available in administrative and research databases. Finally, 
methods for uniform data collection on information on sexual orientation and gender identity are 
in their infancy, despite calls for such data collection from the Institute of Medicine, among 
others.
12
 
 
Recommendations 
• A standard set of race and ethnicity as well as sociodemographic measures should be agreed 
upon by the cancer health disparity research community. To the greatest extent possible, these 
core measures should be included in clinical registries and in research protocols funded by the 
National Institutes of Health, private foundations, and pharmaceutical companies regardless of 
the hypothesis being tested. As much as possible, the most granular measures possible should be 
selected, and, in the case of race and ethnicity, questions should address ancestry, immigration 
status, and enclave effects. To assess neighborhood and structural effects on health, measures of 
the built (man-made) environment should be included, or patient address should be collected and 
geocoded, so that physical and other contextual effects, in addition to individual-level effects, 
can be considered.
13
 
• Measures of race, ethnicity, sexual orientation, and gender identity should be self-reported, not 
based on observation, and should be collected by all researchers and all clinical settings on all of 
their study subjects and patients. To understand the environment and the context in which 
patients live, the expertise of epidemiologists and other social scientists should be used, and 
community members should be engaged in disparities research endeavors. 
• Providers, patients, and the public should be educated regarding the rationale for and 
importance of collecting sociodemographic data, some of which may be perceived as potentially 
sensitive questions (eg, sexual orientation and gender identity). Standard guidelines to facilitate 
collection and to mitigate patient or participant concerns should be offered. 
• The cancer health disparity community should establish reporting standards for measurement 
variables, similar to CONSORT and PRISMA guidelines, for journal editors and peer reviewers 
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to facilitate and standardize assessment of the quality of the data collection method when 
evaluating health disparity research findings for publication. For example, justification for 
selection of socioeconomic measures should be provided; constructs of race and ethnicity should 
be provided in the description of the conceptual framework and sampling frame; and other 
measures that define medically underserved populations, such as low-literacy populations, 
should be clearly specified. When publications fall short of these guidelines, authors should 
explicitly acknowledge the limitations of their research when key factors, such as wealth, are not 
accounted for. Statements such as “findings controlled for socioeconomic status” would no 
longer be sufficient in most publications. Researchers should be asked to provide their study 
protocols, just as clinical trialists do now. 
 
BIOLOGIC AND ENVIRONMENTAL DETERMINANTS OF CANCER INCIDENCE 
Background 
Disparities in cancer incidence are pronounced and longstanding. Drivers of these disparities are 
multifactorial and multilevel, and they include sociodemographic factors, access to health care, 
risk factor profiles and lifestyle/health habits, cultural perceptions, biologic differences, and 
genetic predisposition. Disparities in cancers for which single etiologic factors account for a 
substantial proportion of disease (eg, human papillomavirus and cervical cancer, or Helicobacter 
pylori and stomach cancer) can be reasonably understood and explained, but disparities for many 
of the common etiologically heterogeneous cancers, such as breast, prostate, and colorectal 
cancers, remain much less well understood. 
 
Current Issues/State of Knowledge 
Multilevel approaches are needed to advance knowledge relevant to addressing disparities in 
cancer incidence rates. One approach is to design and implement observational studies focused 
on a population in which disparities exist to advance knowledge about etiology and to inform 
novel prevention strategies. A successful example of such an effort is the African American 
Breast Cancer Epidemiology and Risk (AMBER) Consortium, a multicenter consortium that has 
combined data and biospecimens from 7,500 African American patients with breast cancer and 
17,000 healthy controls, representing the largest study of breast cancer in African American 
women in the United States.
14 
It has yielded a number of insights on multilevel risk factors 
specific to the major molecular subtypes of breast cancer among African American women.
15-17
 
There is also a need for studies focused on identifying the genetic contributors to cancer health 
disparities. Recent work has focused on the prioritization of candidate variants relevant to 
prostate cancer risk within the context of genetic ancestry (based on ancestry informative 
markers) across those with European, African, Japanese, or Latino ancestry.
18
 Furthermore, the 
African Ancestry Prostate Cancer GWAS Consortium has reported on susceptibility loci for 
aggressive prostate cancer specific to men of African ancestry.
19 
 
Although some cancer risk factors are well established, the biologic mechanisms through which 
their impact on cancer risk varies across different populations remain incompletely understood. 
For example, variations in diet are hypothesized to be the primary driver of the dramatic 
variations in colorectal cancer incidence rates observed across populations. Recent research has 
evaluated the impact that different diets have on microbiota composition and function, which in 
turn affects the production of metabolites that either promote mucosal health or are 
inflammatory/neoplastic in the gut. A study that compared Americans with African ancestry 
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(who have a relatively high incidence of colorectal cancer) to rural South Africans (who have a 
comparatively very low colorectal cancer incidence rate) demonstrated that a typical US diet 
with high meat and fat intake increases mucosal proliferation rates (a marker of cancer risk) 
when fed to both populations, whereas typical high-fiber South African diets were associated 
with low proliferation rates when fed to both groups. This demonstrates that diet can have a 
profound and fairly immediate impact on the gut microbiome that can be either promote or 
suppress tumors.
20
 
 
Recommendations 
• Fund additional collaborative transdisciplinary studies focused on populations with unequal 
burdens of particular cancers (eg, the AMBER Consortium and the African Ancestry Prostate 
Cancer GWAS Consortium). 
• Ensure that major initiatives, such as The Cancer Genome Atlas, the Precision Medicine 
Initiative, and the NCI Cancer Moonshot Initiative, include sufficient representation from 
minority populations and address questions relevant to the reduction of cancer health disparities. 
• Engage the research community to bring cutting-edge research tools to the study of cancer 
health disparities (eg, next-generation sequencing, various omics platforms, and drug discovery 
and development) that should include dedicated research in how Ancestry Informative Markers 
(AIMS) can best be integrated with the increasingly complex sociodemographic data outlined in 
the Determinants of Cancer section. 
• Develop international studies aimed at better understanding the roles of environmental, 
lifestyle, and cultural factors on differences in cancer incidences across countries and regions. 
 
BIOLOGIC, ENVIRONMENTAL AND SYSTEM-LEVEL DETERMINANTS OF POST-
DIAGNOSIS SURVIVAL 
Background 
Cancer outcome disparities are well documented for racial and ethnic minorities, and 
presentation at more advanced stages of cancer explains much of this difference. However, even 
when controlling for the stage of cancer at diagnosis, the survival disparities persist. What is 
most concerning is that rather than improving over time, for cancers such as colon cancer, the 
stage-specific disparities are actually worsening.
21
 The reason for this growing disparity is not 
completely clear but involves socioeconomic issues such as education status and the level of 
insurance and access to medical care. Even in studies that normalize socioeconomic issues (with 
the limitations cited in the Determinants of Cancer section), disparities that disproportionally 
affect US minority populations can still be demonstrated for several cancers and may highlight 
the not-so-well-understood interplay between genetic predisposition and environmental 
exposure, such as lifestyle and diet, that modifies cancer risk.
22,23
 Ultimately, growing 
postdiagnosis survival disparities are caused by the interplay of system, social, biologic, and 
environmental factors. Documenting and addressing each of these and their interactions are key 
to eliminating these disparities. 
 
Current Issues/State of Knowledge 
System. The role of system-level and social determinants in explaining cancer health disparities 
is best demonstrated by recognizing that disparities vary widely across the United States; some 
states show almost no disparities, whereas others show striking ones.
24 
We also know that 
disparities in treatment of cancer differ and that when treatment differences are accounted for, 
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either through the use of standardized therapies on a clinical trial or through multivariable 
modeling, cancer-specific survival disparities often disappear. We also have clear examples of 
successful system-level reform.
21,25-26
 We know, therefore, this is a solvable problem. 
 
The key step toward improving care and reducing cancer health disparities requires accurate 
measurement of meaningful variables, fed back in real time to key stakeholders in the system, 
followed by meaningful action and continued monitoring to ensure that the action was 
successful. Determining meaningful measurement across the cancer spectrum may vary by 
sociocultural factors and requires patient and stakeholder input. These system-based practices 
formed the core of a recent Institute of Medicine report, “Systems Practices for the Care of 
Socially At-Risk Populations.”
27
 Systems can be thought of at a macro level, such as state, 
county, or city governments, all the way down to the individual practice or physician level. 
Implementation science can inform the best approaches to ensure delivery of high-quality cancer 
care. 
 
Gene/host/environment. Cancers can start as a result of chronic inflammation, and inflammation 
can modify the behavior of cancer. Biomarkers, such as elevated microsatellite alterations at 
selected tetranucleotide repeats (EMAST) that can be detected from inflammation-laden cancers, 
are associated with worse patient outcome and increased metastasis and appear to be more 
common among African Americans. Microsatellite-unstable (MSI) cancers, which have an 
overall good prognosis, may be half as common among African Americans compared with 
whites.
28
 Both EMAST and MSI have implications for (1) chemotherapeutic response and (2) 
immunotherapeutic response. In terms of race, these aspects have not been studied. Furthermore, 
there is much evidence that the microbiome can influence (1) inflammation, (2) response to 
chemotherapy, and (3) cancer or precancerous lesion formation; also, the microbiome itself can 
be determined by diet and other factors. These aspects have not been examined with race in 
mind. Additionally, driver genes may be different within the same type of cancer from patients 
with different genetic backgrounds, which have implications for correct, definitive therapeutic 
approaches.
29
 
 
Most studies that use human specimens to study aspects of cancer and race or ethnicity come 
from limited individual collections with little linked clinical-epidemiologic information, with 
rare exception. The exceptions tend to be NCI-funded projects, such as the North Carolina Colon 
Cancer Study, in which peer review and thoughtful input about how the collection was made 
with controls, surveys, and linked information to make the collection more meaningful, 
comprehensive in information, potentially useful for other future studies, and possessed of 
longevity. However, these types of collections or biorepositories, which include tumor and 
nontumor samples, have not been created from diverse samples representative of the US Census 
population. 
 
Recommendations 
System 
• Develop, in concert with representatives of at-risk populations, and validate cancer quality 
metrics across the cancer spectrum most relevant to oncology practices that operate in low-
resource environments. 
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• Design risk-adjustment methodologies for oncology practices in low-resource environments 
that hold them accountable for high-quality care but do not penalize them for taking care of high-
risk patients. 
• Assess the clinical and financial effectiveness of alternative oncology payment models that 
provide up-front infrastructure investment for practices in low-resource environments. 
• Hold systems accountable for real-time monitoring and feedback of cancer health disparities. 
These systems should include city and county health departments and state Medicaid programs. 
An excellent example of this is Rapid Quality Reporting System (RQRS) developed by the 
Commission on Cancer (CoC). The RQRS is a reporting and quality-improvement tool that 
provides real clinical time assessment of hospital-level adherence to quality of cancer care 
measures. This is a mandatory reporting program for all CoC sites as of January 1, 2017.
30
 
 
Gene/host/environment. 
• Develop or enhance existing national biorepositories that contain specimens of solid cancers 
from underserved populations (eg, racial/ethnic minorities, low SES, medically uninsured, 
gender minorities) that are at least representative of the population demographics of those 
groups, and oversample individuals from these groups in biorepositories aimed to address 
disparities. The National Institutes of Health can use P20, U01, and U56 mechanisms for their 
development, with specimen and data-sharing plans available to those who might meet criteria to 
use them and program announcements designed to address the limitations of current 
biorepositories for cancer health disparities research. These collections should be annotated with 
appropriate sociodemographic information, as outlined in the Determinants of Cancer section. 
• Fund additional studies to determine the role of inflammation and the microbiome on the 
biology of cancer and its effects on cancer among underserved groups and to determine how 
inflammation and the microbiome affect cancer staging, stage-specific survival, and recurrence 
rates. 
• Fund additional studies of human population genetics to inform interpretations of disparate 
drug effects of cancer therapy across patient populations.
31
 
 
ADVANCING COMMUNITY ENGAGEMENT STRATEGIES THROUGHOUT THE 
CANCER CARE CONTINUUM 
Background 
Current models of health care delivery are highly focused on the use of technology and 
innovation to improve patient outcomes across disease processes, as demonstrated by the focus 
on precision medicine in cancer treatment.
32-35
 Although oncology attempts to embrace this 
approach, the impact of innovative treatments has been hampered by poor translation of 
innovation into health care systems and patients from diverse community settings.
36,37
 As 
precision medicine in cancer is accelerated as part of the National Cancer Moonshot and other 
NCI initiatives, the importance of community engagement to ensure that all patients benefit from 
these advances cannot be overlooked. Cancer health disparities must be taken into consideration 
in the design, execution, and evaluation of all such programs. 
 
Current Issues/State of Knowledge 
Community-engaged research (CER) has been documented as an effective, beneficial method for 
engaging communities and formulating research that has relevance and impact for both 
researchers and affected communities.
39-42
 Involving relevant community stakeholders in 
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research at the planning stages allows for a deeper understanding of community needs, allows 
researchers to have an iterative method for evaluating research questions in an active realistic 
milieu, and simultaneously creates a valuable vehicle for active dissemination of the research 
findings into the communities they are intended to serve. CER offers the potential to improve 
process and outcomes in several areas, including care delivery, continuity of care, managing 
comorbidities, and supportive care.
42
 
 
Unfortunately, there is a dearth of support for oncology health professionals who choose to work 
in CER, given its necessity for infrastructure and relationship building, the complex personal 
interactions with communities and community organizations, and the need to establish long-term 
benefits to the community after the research project is completed. Importantly, CER requires not 
only a broad range of expertise across multiple disciplines, but also investigators skilled in a 
team science approach.
43
 The benefit of this type of team science has been touted across 
disciplines; however, its implementation has been limited.
44 
 
A lack of workforce diversity has been identified as a barrier to improving access to care for 
underserved minority groups as well as to advancing research on health disparities.
45,46
 
Organizations, including ASCO and the American Society of Hematology, have sought to 
increase workforce diversity in oncology through awards and mentoring programs that expose 
underrepresented minorities to careers in oncology at the medical student, resident, and 
fellowship levels. In addition, the NCI Center to Reduce Cancer Health Disparities and the 
American Association for Cancer Research administer several programs aimed at training the 
next generation of competitive researchers in cancer and cancer health disparities research. 
Increased efforts of these types are needed to develop an oncology workforce that reflects the 
diversity of the patients it serves. 
 
Finally, CER does not often align with most traditional grant timelines and will require 
investment on behalf of the research institutions in both personnel and resources. Without such 
an investment, it will remain difficult to create a true synergy between CER and the rapid 
discoveries that occur in cancer research. 
 
Recommendations 
• Specific criteria should be developed by experts in CER to aid cancer centers in establishing 
meaningful community research partners. 
• Requirements for NCI comprehensive cancer center designation should include meeting 
meaningful CER criteria including sustainability plans for maintaining community relationships 
beyond typical grant funding cycles. 
• To ensure a diverse workforce with varied life experiences, research and mentoring efforts 
aimed at improving workforce diversity in oncology should be expanded. 
• Academic deans and chairs should establish separate promotion criteria, such as an extended 
promotion “clock,” to account for the added infrastructure and relationship-building time 
required for this type of research. 
 
REDESIGNING CLINICAL TRIALS TO ACKNOWLEDGE AND ADDRESS CANCER 
HEALTH DISPARITIES 
Background 
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Clinical trials are the most important and reliable means available to provide scientific evidence 
for effective care and management of patients with cancer and individuals at risk for cancer.
47
 
Complex trials that incorporate advanced technologies necessitate new approaches from clinical 
care teams and diverse oncology practices. Because the putative goal of clinical trials is to 
provide evidence that is generalizable, future trials must include research questions that consider 
the multifactorial and multilevel components that characterize populations with the greatest 
cancer burden. This section proposes strategies to advance disparities research within the current 
cancer clinical trials system and/or within a new network of disparities-focused programs. 
 
Current Issues/State of Knowledge 
Stringent criteria for participation in cancer clinical trials and common procedures for providing 
trial information have been barriers to enrollment for racial/ethnic minorities; rural residents; 
older patients (≥ 65 years); and patients with lower SES, limited English proficiency, low health 
literacy, and comorbidities. The incidence of high rates of chronic diseases and increasing risk 
factors for chronic diseases, such as obesity and early-onset diabetes, must inform eligibility 
criteria to represent these populations fully in cancer protocols. As an example, African 
Americans bear a disproportionate burden of the comorbidities that typically exclude participants 
from studies, and it is difficult to determine which comorbidities could be reasonably eliminated 
as exclusion criteria or could be sufficiently monitored or managed within the study 
framework.
48
 In addition to those front-end enrollment barriers, experience from cancer 
prevention and treatment trials also has shown that underrepresented populations often are 
enrolled later in the recruitment process, and subsequent power calculations frequently do not 
support subpopulation analyses. 
 
Recruitment and retention rates are key variables that influence the outcome of clinical cancer 
studies, particularly those trials in which minorities have disproportionately higher disease 
burdens, such as breast, prostate, colorectal, and lung cancers.
49
 In prevention, screening, and 
treatment trials, suboptimal recruitment and retention rates exist. Similarly, lower rates exist for 
those patients who transition from pediatric to adolescent and young-adult cancers. Many issues, 
such as prevailing sociodemographics, trust issues, comorbidity burdens, and competing 
priorities, contribute to the situation.
50
 However, community engagement is vital to address the 
fundamental recruitment and retention challenges that cloud the clinical trials setting. CER has 
been demonstrated to promote trust, colearning, capacity building, and the sharing and 
dissemination of information needed for short and long-term success.
51
 As an example, the 
Community-Based Retention Intervention Study evaluated the effectiveness of using community 
health advisors to promote retention and adherence in low-income and rural populations and 
found that community health advisors can be trained to serve as research partners and can be 
effective for improvement of retention and adherence.
52
 
 
Finally, existing federally funded cancer clinical trial networks and pharmaceutical partners 
require an ever-complex array of biospecimens, often to be collected at multiple time points. 
More thought should be given to how best to augment the capacity of biospecimen teams and the 
study infrastructures (eg, surgical and pathology departments) needed to support collection and 
preparation of adequate specimens from low-resource institutions and centers that seek to recruit 
under-represented populations. 
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Recommendations 
• More members of minority health care teams/community investigators need to be involved in 
study design, with specific emphasis on inclusion and exclusion criteria. 
• Successful tools of CER need to be used and evaluated to inform underrepresented populations 
about clinical trials and improve recruitment of these populations to clinical trials. 
• Sponsors of clinical trials and agencies, such as the Centers for Medicare & Medicaid Services, 
must collaborate to eliminate cost and coverage barriers to clinical trial participation. It is 
particularly important for the Medicaid program in all 50 states to cover the routine care costs of 
clinical trials. 
• A better understanding of how best to help low-resourced institutions recruit participant to 
trials, when there is an ever-increasing requirement to collect complex biospecimens, is needed. 
• Trial design should be fostered to extend the recruitment periods to meet designated targets of 
underrepresented populations. 
• Disparities questions should be integrated into efficacy questions to assess a hypothesis-driven 
correlative science question, or to test an innovative recruitment strategy. One example of trials 
that offer more real-world conditions and greater efficiency is the reciprocal control design, in 
which participants in each arm of the reciprocal control trial receive an intervention for a 
particular disease but also serve as controls for a different intervention and disease in the other 
arm. 
• Funding mechanisms for clinical trials programs that focus exclusively on cancer health 
disparities are needed. 
 
Conclusion 
The field of cancer health disparities has evolved into a complex science and an established 
multidisciplinary field of cancer research. Unfortunately, the rigor required to conduct this 
research has not been uniformly applied, and the infrastructure needed to take it to the next level, 
where lasting solutions can be found, is limited. The purpose of this article, which has been 
jointly written by experts from these four esteemed organizations, is to guide the development of 
advances in this area. Our hope is that this statement will be used by both public and private 
organizations to inform specific investments made to improve cancer health disparities research, 
thereby ultimately eliminating identified disparities in cancer incidence, quality of care, and 
outcomes. 
 
Several recommendations for action items emerged. 
1. The tools needed to define sociodemographic and economic characteristics of individuals and 
groups have become very sophisticated, and it is incumbent upon researchers and those who fund 
and publish their work to require that the highest-quality tools to measure the most granular data 
are used. 
2. If our intention is to study minority and underserved populations in a “cell to society” manner, 
then we need to create multiple consortia explicitly established to gather all of the relevant 
biospecimen, clinical, individual, and contextual data needed to conduct adequately powered 
hypothesis-driven health disparities research. The development of a health disparities research 
network, similar to the Cancer and Aging Research Group, could aid in designing such studies 
and recruiting individuals to participate.
54
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3. Best-practice strategies must be designed and used to ensure that underserved patients, their 
providers, and institutions are adequately targeted and informed about opportunities to 
participate in research studies and clinical trials. 
4. To develop a comprehensive approach to health disparities, we need researchers who are 
adequately trained in community-engaged research. In addition, criteria for appropriate academic 
promotions that account for the time to conduct community-engaged research should be 
established for these researchers. Funding for community-engaged research should be made with 
the expectation that the enhanced infrastructure and outreach made possible by grants should be 
sustained beyond funding cycles. 
5. Because patients with cancer exist in a web of health care systems, these systems have an 
obligation to understand how these patients are being treated in real time and to intervene when 
system errors occur. 
 
We have clearly entered a new phase in cancer health disparities research—one that has the 
potential to benefit significantly from collaborations across disciplines and sectors. Given the 
looming crisis in cancer incidence and mortality that disproportionately affects minorities and the 
medically underserved, it is our collective hope that in this period of cancer research when 
significant breakthroughs are being discovered, there will be opportunities to apply this new 
knowledge to all populations, and thus eliminate cancer health disparities for current and future 
generations. 
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